文献速递腹部CT

基于去脂体重的个体化对比剂方案优化肝脏强化:前瞻性多中心研究

Prospective multicenter study on personalized and optimized MDCT contrast protocols: results on liver enhancement.
PubMed 文献 · Eur Radiol · 2021-04-29

结果显示基于600 mgI/kg去脂体重的方案(G4)肝脏强化中位数53.2 HU最接近目标诊断值50 HU,强化均匀性最佳(IQR 14.5 HU),且碘负荷最低(中位数26.0 gI)。

要点

  • 基于去脂体重600 mgI/kg的个体化对比剂方案可提供均匀且诊断适宜的肝脏强化。
  • 该方案较固定体积或其他体重基方案显著降低碘负荷,并减少患者间强化差异。
  • 肿瘤随访肝脏CT可采用600 mgI/kg去脂体重的对比剂方案。

核心结论

  • 基于600 mgI/kg去脂体重的个体化对比剂方案实现了诊断优化的肝脏强化并改善了患者间强化均匀性,同时显著降低碘负荷。

关键影像表现/征象

  • 肝脏强化中位数从G1的77.0 HU、G2的71.3 HU、G3的65.1 HU降至G4的53.2 HU,各组间差异显著(p < 0.001)。
  • 强化四分位距从G1的26.5 HU、G2的26.0 HU、G3的17.8 HU逐渐缩小至G4的14.5 HU。

诊断标准与关键数值

  • 目标诊断强化值为50 HU;G4组(600 mgI/kg去脂体重)肝脏强化中位数53.2 HU最接近该目标。
  • G4组碘剂量中位数26.0 gI,显著低于G3的33.9 gI、G2的38.8 gI和G1的37 gI(p < 0.001)。

临床应用与阅片要点

  • 对于肝脏CT增强检查,尤其是肿瘤随访,可采用基于去脂体重的600 mgI/kg对比剂方案以优化强化水平并降低碘负荷。
  • 使用去脂体重而非总体重作为体型参数可能更准确地预测肝脏强化程度。

局限性

  • 研究未报告样本量计算、盲法及随机化方法等细节。
  • 仅评估了肝脏强化,未涉及病灶检出率或诊断准确性的临床结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To determine a personalized and optimized contrast injection protocol for a uniform and optimal diagnostic level of liver parenchymal enhancement, in a large patient population enrolled in a multicenter study.

METHODS: Six hundred ninety-two patients who underwent a standardized multi-phase liver CT examination were prospectively assigned to one contrast media (CM) protocol group: G1 (100 mL fixed volume, 37 gI); G2 (600 mgI/kg of total body weight (TBW)); G3 (750 mgI/kg of fat-free mass (FFM)), and G4 (600 mgI/kg of FFM). Change in liver parenchyma CT number between unenhanced and contrast-enhanced images was measured by two radiologists, on 3-mm pre-contrast and portal phase axial reconstructions. The enhancement histograms were compared across CM protocols, specifically according to a target diagnostic value of 50 HU. The total amount of iodine dose was also compared among protocols by median and interquartile range (IQR). The Kruskal-Wallis and Mann-Whitney U tests were used to assess significant differences (p < 0.005), as appropriate.

RESULTS: A significant difference (p < 0.001) was found across the groups with liver enhancement decreasing from median over-enhanced values of 77.0 (G1), 71.3 (G2), and 65.1 (G3) to a target enhancement of 53.2 HU for G4. Enhancement IQR was progressively reduced from 26.5 HU (G1), 26.0 HU (G2), and 17.8 HU (G3) to 14.5 HU (G4). G4 showed a median iodine dose of 26.0 gI, significantly lower (p < 0.001) than G3 (33.9 gI), G2 (38.8 gI), and G1 (37 gI).

CONCLUSIONS: The 600 mgI/kg FFM-based protocol enabled a diagnostically optimized liver enhancement and improved patient-to-patient enhancement uniformity, while significantly reducing iodine load.

KEY POINTS: • Consistent and clinically adequate liver enhancement is observed with personalized and optimized contrast injection protocol. • Fat-free mass is an appropriate body size parameter for correlation with liver parenchymal enhancement. • Diagnostic oncology follow-up liver CT examinations may be obtained using 600 mgI/kg of FFM.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Zanca F, Brat HG, Pujadas P, et al. Prospective multicenter study on personalized and optimized MDCT contrast protocols: results on liver enhancement. Eur Radiol. 2021. PMID: 33914115. doi:10.1007/s00330-021-07953-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。